Clavis Pharma appoints Olav Hellebø as Chief Executive Officer

12-Jan-2010

Clavis Pharma ASA announced that it has appointed Olav Hellebø as its new Chief Executive Officer (CEO). Mr Hellebø, who joins Clavis Pharma from UCB Pharma, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mr Hellebø will take up his position on 1st February 2010.

Olav Hellebø (age 44) is an experienced pharmaceutical executive who has held senior positions in the pharmaceutical industry in both Europe and the USA. He joins Clavis Pharma from UCB, the global biopharmaceutical company where he was Senior Vice President, UCB Pharma and President of Immunology Operations. In this position he built and led the global organization responsible for the successful registration and launch of Cimzia®, UCB’s new antibody drug for the treatment of rheumatoid arthritis and Crohn’s disease. From 2003 to 2004 Mr Hellebø was Chief Operating Officer of Novartis UK and prior to that held a series of senior international roles at Schering Plough, the last as head of Schering Plough’s Oncology Biotech Division in the USA. Mr Hellebø graduated in business studies from Hofstra University, New York and received an MBA from IESE, Barcelona.

Geir Christian Melen, Clavis Pharma’s current CEO will hand over to Olav Hellebø on 1st February 2010 and will continue with the Company as an adviser for a transition period expected to last until end of June.

https://www.bionity.com/en/news/111608/clavis-pharma-appoints-olav-helleb-as-chief-executive-officer.html